Organization
Duke Cancer Network
2 abstracts
Abstract
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Chesapeake Urology Research Associates, Duke Cancer Network,
Abstract
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Virginia Oncology Associates, U.S. Oncology Research, Barbara Ann Karmanos Cancer Institute,